Analyst Research

Report Title Price
Provider: Wright Reports
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cempra Inc Secures $58 Million Contract To Develop Antibiotic For Pediatric Use And Biodefense By Biomedical Advanced Research And Development Authority

Tuesday, 28 May 2013 09:15am EDT 

Cempra Inc announced that the Biomedical Advanced Research and Development Authority ( BARDA ) has awarded Cempra with a five year contract valued up to $58 million for the development of solithromycin to treat infections in pediatric populations and for the treatment of infections by bioterror threat pathogens. Solithromycin, Cempra's lead product candidate, is a fourth generation macrolide antibiotic in the fluoroketolide family that is currently in Phase 3 development for community-acquired bacterial pneumonia (CABP) in adults. 

Company Quote

1.72 +13.84%
11:38am EDT